nad has been researched along with alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cosi, C; Guerin, K; Koek, W; Marien, M; Rollet, K | 1 |
1 other study(ies) available for nad and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
| Article | Year |
|---|---|
The PARP inhibitor benzamide protects against kainate and NMDA but not AMPA lesioning of the mouse striatum in vivo.
Topics: Adenosine Triphosphate; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Benzamides; Brain Injuries; Chromatography, High Pressure Liquid; Corpus Striatum; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Agonists; Glial Fibrillary Acidic Protein; Immunohistochemistry; Kainic Acid; Male; Mice; Mice, Inbred C57BL; N-Methylaspartate; NAD; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Time Factors | 2004 |